Article Sidebar

PDF
Date Published: 17/10/2022
Abstract Views: 3068
Views PDF: 649
DOI: https://doi.org/10.51298/vmj.v519i1.3516
Issue
Vol. 519 No. 1 (2022)
Section
Các bài báo
How to Cite
Thị Quỳnh Nga, N. ., Đặng Tú Nguyên, L. ., Phước Thành Nhân, L. ., Văn Đạt, T. ., & Thị Hải Yến, N. . (2022). COST-EFFECTIVENESS ANALYSIS OF ESOMEPRAZOLE COMPARED TO PANTOPRAZOLE IN GASTROESOPHAGEAL REFLUX DISEASE PATIENT WITH EROSIVE OESOPHAGITIS IN VIETNAM. Vietnam Medical Journal, 519(1). https://doi.org/10.51298/vmj.v519i1.3516

COST-EFFECTIVENESS ANALYSIS OF ESOMEPRAZOLE COMPARED TO PANTOPRAZOLE IN GASTROESOPHAGEAL REFLUX DISEASE PATIENT WITH EROSIVE OESOPHAGITIS IN VIETNAM

Nguyễn Thị Quỳnh Nga1,, Lê Đặng Tú Nguyên1, Lê Phước Thành Nhân2, Trương Văn Đạt1, Nguyễn Thị Hải Yến1
1 University of Medicine and Pharmacy at Ho Chi Minh City
2 Le Van Thinh Hospital

Main Article Content

Abstract

Objectives: Cost-effectiveness analysis of esomeprazole compared to pantoprazole in Gastroesophageal reflux disease (GERD) patient with erosive oesophagitis in Vietnam. Research methods: A decision tree model was employed to assess the associated cost and effectiveness of two PPI drugs esomeprazole and pantoprazole from the payer perspective. Input parameters were extracted from empirical datas of publicized multi-centre and meta-analysis studies. Results were expressed as incremental cost-effectiveness ratio (ICER), results of one-way sensitivity analysis and probabilistic sensitivity analysis. Results: Compared to pantoprazole, the incremental cost-effectiveness ratio (ICER) for esomeprazole was 44574294 VND/QALY, with relatively 0.0016 QALYs gained and an additional cost of 72075.9 VND. Utility value of healed and unhealed group, the unit cost of esomeprazole and pantoprazole are the factors that strongly influence the ICER value. Conclusion: From the payer perspective and compared to WTP recommended by WHO, esomeprazole is cost-effective relative to pantoprazole in the treatment of GERD with erosive oesophagitis in Vietnam.

Article Details

Keywords

Esomeprazole, Pantoprazole, GERD with erosive oesophagitis, Cost-effectiveness, Vietnam

References

1. Zhang D, Liu S, Li Z, Wang & R, Wang R. Global, regional and national burden of gastroesophageal reflux disease, 1990–2019: update from the GBD 2019 study. https:// doi.org/ 101080/0785389020222074535. 2022;54(1):1372–84.
2. Fock KM, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008;23(1):8–22.
3. Hatlebakk JG. Review article: gastric acidity − comparison of esomeprazole with other proton pump inhibitors. Aliment Pharmacol Ther. 2003; 17(1):10–5.
4. Miehlke S, Madisch A, Kirsch C, Lindner F, Kuhlisch E, Laass M, et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study. Aliment Pharmacol Ther. 2005;21(8):963–7.
5. Yokoya Y, Igarashi A, Uda A, Deguchi H, Takeuchi T, Higuchi K. Cost-utility analysis of a “vonoprazan-first” strategy versus “esomeprazole- or rabeprazole-first” strategy in GERD. J Gastroenterol. 2019;54(12):1083–95.
6. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther. 2005;21(6):739–46.
7. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798–810.
8. Wójcik P, Chudziak D, Macioch T, Niewada M. Cost-Effectiveness of Esomeprazole Compared With Other Ppis Currently Reimbursed In Poland In The Treatment of Gerd. Value Heal. 2015; 18(7): A625–6.
9. Wahlqvist P, Dl V, Sd S, Gm D, Jacobs M, Gj L, et al. Esomeprazole Is Cost-Effective Compared With Pantoprazole In The Acute And Maintenance Treatment Of Reflux Esophagitis In Finland. Value Heal. 2005;8:A120.